Cannabinoid | High Risk

Cannabis Flower THC 25% (Dried Herb) (Cannatrek T25 Ruby)

Cannabis Flower THC 25% (Dried Herb) risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Cannatrek T25 Ruby, ANTG Solace.

Source: AllMeds_Curated Updated April 2026

Cannabis Flower THC 25% (Dried Herb) (brand names: Cannatrek T25 Ruby, ANTG Solace) is classified as High risk (7 risk points) by AllMeds. It is a S8 medication under the TGA in Australia. High-potency flower, significant impairment

Key Takeaways

  • TGA Schedule: S8 in Australia
  • Risk level: High (7 points)

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S8 Not PBS listed

Risk Profile

Risk Level High
Risk Points 7
CNS Depressant No
Respiratory Risk No

High-potency flower, significant impairment

Regulatory and Compliance Guidance

When Cannabis Flower THC 25% (Dried Herb) appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.

Australia TGA / PBS / State Schemes

Classified as S8 under the Therapeutic Goods Administration (TGA).

Clinical Evidence

  • Medicinal cannabis prescriptions surge in Australia - ABC News (2024)

    Reporting on the rapid growth of medicinal cannabis prescriptions in Australia via SAS pathway. Notes concerns about evidence base.

    National broadcaster

  • TGA: Medicinal Cannabis Access — THC Products (S8) - TGA (2024)

    THC products are Schedule 8. Require SAS-B or Authorised Prescriber pathway. Strict prescribing and monitoring requirements.

    TGA regulatory framework

  • SIRA: Medicinal Cannabis — S8 Requirements and Driving Impairment - SIRA NSW (2023)

    SIRA notes THC products carry driving impairment risk. NSW drug-driving laws apply regardless of medical authorisation. Insurer approval required.

    NSW workers comp regulator

  • Cannabis-based medicines for chronic neuropathic pain — Cochrane Review - Mücke M, et al. (Cochrane) (2018)

    Cochrane review finding low-quality evidence that cannabis-based medicines may provide some relief for chronic neuropathic pain. Significant adverse effects noted.

    Cochrane systematic review — gold standard for evidence synthesis

Need to assess this medication across your caseload?

Run a full risk assessment including Cannabis Flower THC 25% (Dried Herb) interactions and compliance checks.

AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.

No credit card required. No signup for your first 2 questions.

Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.